Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATAI 
ATAI Life Sciences BV (ATAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: ATAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9
1 Year Target Price $9
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.41% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 583.40M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 7 | Beta 1.48 | 52 Weeks Range 1.03 - 2.98 | Updated Date 07/8/2025 |
52 Weeks Range 1.03 - 2.98 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1239.23% |
Management Effectiveness
Return on Assets (TTM) -26.04% | Return on Equity (TTM) -79.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 511859111 | Price to Sales(TTM) 315.43 |
Enterprise Value 511859111 | Price to Sales(TTM) 315.43 | ||
Enterprise Value to Revenue 274.75 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 212144000 | Shares Floating 111215420 |
Shares Outstanding 212144000 | Shares Floating 111215420 | ||
Percent Insiders 8.22 | Percent Institutions 33.4 |
Upturn AI SWOT
ATAI Life Sciences BV
Company Overview
History and Background
ATAI Life Sciences BV was founded in 2018. It focuses on developing psychedelic and non-psychedelic compounds for various mental health disorders. ATAI went public in 2021.
Core Business Areas
- Drug Development: ATAI invests in and incubates companies developing novel mental health treatments.
- Platform Development: ATAI is building a technology platform to improve the efficiency of drug development and patient care in mental health.
Leadership and Structure
Florian Brand is the CEO and co-founder. The company has a management team with experience in biotech, pharmaceuticals, and venture capital. They operate a decentralized model, investing in and supporting subsidiary companies.
Top Products and Market Share
Key Offerings
- PCN-101 (R-ketamine): Developed by Perception Neuroscience. Targeting Treatment-Resistant Depression. Competitors include Janssen's Spravato (esketamine).
- RL-007: Developed by Revivo Bio, it modulates glutamatergic neurotransmission. Targeting Cognitive Impairment Associated with Schizophrenia. Competitors: Currently limited as it is a unique approach.
- VLS-01: Developed by Viridia Life Sciences. Targeting opioid use disorder. Competitors: Methadone and Buprenorphine.
Market Dynamics
Industry Overview
The mental health market is growing due to increasing awareness and unmet needs. Psychedelic-assisted therapies are gaining acceptance.
Positioning
ATAI is a leading player in the psychedelic medicine space, with a diversified portfolio of compounds targeting various mental health conditions. They have a first-mover advantage, but also face regulatory and public perception hurdles.
Total Addressable Market (TAM)
The global mental health market is estimated at hundreds of billions of dollars. ATAI is targeting specific sub-segments like TRD, schizophrenia, and addiction. The TAM for these indications is substantial, positioning ATAI for significant growth potential, if trials are successful.
Upturn SWOT Analysis
Strengths
- Diversified pipeline
- Strong financial backing
- Experienced management team
- Decentralized operating model
- First-mover advantage in psychedelic medicine
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Regulatory uncertainty
- Public perception of psychedelics
- Relatively new company
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Regulatory approval of psychedelic therapies
- Growing acceptance of psychedelic medicine
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Negative publicity surrounding psychedelics
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- JNJ
- AVXL
- GHRS
Competitive Landscape
ATAI's advantage lies in its focus on psychedelic medicine and its diversified pipeline. However, established pharmaceutical companies have greater resources and experience in drug development and commercialization.
Major Acquisitions
Perception Neuroscience
- Year: 2020
- Acquisition Price (USD millions): 20.7
- Strategic Rationale: Acquisition of Perception Neuroscience provided ATAI with access to PCN-101 (R-ketamine), a promising treatment for TRD.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by acquisitions of promising compounds and companies in the mental health space.
Future Projections: Analysts project significant revenue growth if ATAI's key compounds receive regulatory approval. However, projections are highly dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, and exploring new partnerships and acquisitions.
Summary
ATAI Life Sciences is a promising company in the emerging psychedelic medicine space, with a diversified pipeline and strong financial backing. However, it faces significant risks related to clinical trial outcomes, regulatory uncertainty, and public perception. ATAI needs to manage its cash burn carefully and achieve positive clinical trial results to realize its full potential. Its decentralized model allows for innovative drug development but adds inherent risk in terms of oversight.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and is subject to change. Investing in biotech companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ATAI Life Sciences BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-18 | Co-Founder & CEO Dr. Srinivas G. Rao M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://atai.com |
Full time employees 54 | Website https://atai.com | ||
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.